Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Patient Assistance
Product Portfolio
Our Process
Therapeutic Areas
Product Related Issues
About Us
Novartis US at a Glance
Who We Are
Diversity and Inclusion
Our Leadership
Supplier Diversity
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to HCPs & HCOs
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2020
August
Media Release
/
Aug 13, 2020
Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
Read More
Media Release
/
Aug 05, 2020
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Read More
June
Media Release
/
Jun 24, 2020
Novartis announces FDA filing acceptance of Entresto® (sacubitril/valsartan) for patients with heart failure with preserved ejection fraction (HFpEF)
Read More
Media Release
/
Jun 16, 2020
Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
Read More
Media Release
/
Jun 16, 2020
Novartis ILARIS® (canakinumab) receives FDA approval for new indication to treat Adult-Onset Still’s Disease (AOSD)
Read More
Media Release
/
Jun 15, 2020
Novartis manufactures and donates 27,000 units of hand sanitizer to New York State
Read More
Media Release
/
Jun 11, 2020
U.S. FDA approves updated Novartis BEOVU® label, to include additional safety information
Read More
May
Media Release
/
May 29, 2020
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
Read More
Media Release
/
May 27, 2020
Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
Read More
Media Release
/
May 27, 2020
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
Page
1
of 5
Page
2
of 5
Current page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
Related Links
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
You are here
Home
›
News